58
Participants
Start Date
December 9, 2019
Primary Completion Date
March 15, 2022
Study Completion Date
October 31, 2024
Ravulizumab
Participants will receive a weight-based loading dose of ravulizumab via IV infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until end of the Long-Term Extension Period.
Research Site, Vienna
Research Site, Camperdown
Research Site, Fitzroy
Research Site, Aarhus
Research Site, Berlin
Research Site, Goyang-si
Research Site, Washington D.C.
Research Site, Gallarate
Research Site, Madrid
Research Site, Málaga
Research Site, Miami
Research Site, Jackson
Research Site, Cincinnati
Research Site, Rochester
Research Site, St Louis
Research Site, Strasbourg
Research Site, Houston
Research Site, Aurora
Research Site, Napoli
Research Site, Fort Collins
Research Site, München
Research Site, Cefalù
Research Site, Boston
Research Site, Burnaby
Research Site, Leipzig
Research Site, Roma
Research Site, Rome
Research Site, Chiba
Research Site, Fukuoka
Research Site, Kawagoe-shi
Research Site, Niigata
Research Site, Sendai
Research Site, Sendai
Research Site, Katowice
Research Site, Lódz
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Oxford
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY